Michael Grunwald, MD
Hematology · Charlotte, NCNPI 1356495949
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $280,676 of the $343,615 with a category attached, or 81.7%. 33 manufacturers reported payments, led by Daiichi Sankyo Inc. at 28.4% of the total. Among hematology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 386 payments — averaging $890.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$98K
- Incyte Corporation$71K
- Pfizer$19K
- Bristol Myers Squibb$17K
- Astellas Pharma Global Development$16K
- Sobi, Inc$16K
- plus $107K from 27 others
Across 206 payments — averaging $5642.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$628K
- Janssen Research & Development, LLC$408K
- Genentech, Inc.$61K
- National Marrow Donor Program$55K
- Amgen$8K
- Merck$1K
- plus $48 from 1 others
What the payments were for
- Consulting fees$280,67682%
- Speaking & faculty fees$35,52410%
- Travel & lodging$19,0386%
- Food & beverage$8,3772%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 113 | $97,571 |
| Incyte Corporation | 102 | $70,604 |
| Pfizer | 22 | $19,196 |
| Bristol Myers Squibb | 12 | $16,619 |
| Astellas Pharma Global Development | 5 | $16,430 |
| Sobi, Inc | 8 | $15,988 |
| Sanofi-aventis U.S. LLC | 7 | $10,046 |
| Geron Corporation | 12 | $7,612 |
| Amgen | 13 | $6,972 |
| Blueprint Medicines Corporation | 3 | $6,025 |
| Astellas Pharma US Inc | 5 | $5,908 |
| CTI Biopharma Corp. | 6 | $5,861 |
| Stemline Therapeutics Inc. | 2 | $5,650 |
| Sanofi | 6 | $5,562 |
| Servier Pharmaceuticals LLC | 2 | $5,220 |
| Genentech, Inc. | 6 | $5,183 |
| Shorla Oncology Inc. | 1 | $4,950 |
| E.r. Squibb & Sons, L.L.C. | 5 | $4,513 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $4,208 |
| GSK | 4 | $4,082 |
| Autolus Inc | 4 | $3,820 |
| Agios Pharmaceuticals, Inc. | 9 | $3,502 |
| AbbVie | 2 | $2,775 |
| Pharmacosmos Therapeutics Inc. | 5 | $2,714 |
| Jazz Pharmaceuticals Inc. | 1 | $2,560 |
| Sanofi US Services Inc. | 2 | $2,315 |
| Novartis | 4 | $2,147 |
| Gilead(2 entities) | 2 | $1,979 |
| National Marrow Donor Program | 7 | $1,927 |
| Merck | 9 | $1,159 |
| AstraZeneca | 2 | $400 |
| Neuronetics, Inc. | 1 | $106 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$343,615 in reported general payments places this provider in the 90th percentile of 65 hematology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 122 | $1,983,291 |
| VonjoPacritinib Citrate | 22 | $558,890 |
| TasignaNilotinib Hcl | 13 | $244,009 |
| OnuregAzacitidine | 16 | $233,059 |
| RezurockBelumosudil Mesylate | 13 | $230,861 |
| CresembaIsavuconazonium Sulfate | 16 | $96,139 |
| VenclextaVenetoclax | 28 | $78,803 |
| PegasysPeginterferon Alfa-2a | 23 | $78,802 |
| Posaconazole | 28 | $35,711 |
| Imatinib Mesylate | 15 | $16,198 |
| Diphenhydramine Hcl | 18 | $4,321 |
| Pantoprazole Sodium | 11 | $2,854 |
| Acyclovir | 79 | $1,487 |
| ValacyclovirValacyclovir Hcl | 12 | $1,350 |
| Potassium Chloride | 21 | $798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $70,604 | $1,983,291122 claims |
| NovartisTasigna | $2,147 | $244,00913 claims |
| E.r. Squibb & Sons, L.L.C.Onureg | $4,513 | $233,05916 claims |
| Sanofi-aventis U.S. LLCRezurock | $10,046 | $230,86113 claims |
| Astellas Pharma US IncCresemba | $5,908 | $96,13916 claims |
| AbbVieVenclexta | $2,775 | $78,80328 claims |
| Genentech, Inc.Pegasys | $5,183 | $78,80223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 65 hematology providers in North Carolina.
Other hematology in Charlotte
- Ryan JacobsCharlotte$1.5M
- Alan Zausner SkarbnikCharlotte$1.1M
- Raymond ThertulienCharlotte$561K
- Ruben MesaCharlotte$384K
- Nilay ShahCharlotte$228K
- Peter VoorheesCharlotte$157K
- Patricia KropfCharlotte$122K
- Arielle HeekeCharlotte$88K
- Earle BurgessCharlotte$75K
- Omotayo FasanCharlotte$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.